Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
US Stock Markets

| More

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19

Posted On: 2020-03-31 09:54:19


Johnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company's manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. The Company expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.

Through a landmark new partnership, BARDA, which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services, and Johnson & Johnson together have committed more than $1 billion of investment to co-fund vaccine research, development, and clinical testing. Johnson & Johnson will use its validated vaccine platform and is allocating resources, including personnel and infrastructure globally, as needed, to focus on these efforts. Separately, BARDA and the Company have provided additional funding that will enable expansion of their ongoing work to identify potential antiviral treatments against the novel coronavirus.

As part of its commitment, Johnson & Johnson is also expanding the Company's global manufacturing capacity, including through the establishment of new U.S. vaccine manufacturing capabilities and scaling up capacity in other countries. The additional capacity will assist in the rapid production of a vaccine and will enable the supply of more than one billion doses of a safe and effective vaccine globally. The Company plans to begin production at risk imminently and is committed to bringing an affordable vaccine to the public on a not-for-profit basis for emergency pandemic use.

Alex Gorsky, Chairman and Chief Executive Officer, Johnson & Johnson, said, "The world is facing an urgent public health crisis and we are committed to doing our part to make a COVID-19 vaccine available and affordable globally as quickly as possible. As the world's largest healthcare company, we feel a deep responsibility to improve the health of people around the world every day. Johnson & Johnson is well positioned through our combination of scientific expertise, operational scale and financial strength to bring our resources in collaboration with others to accelerate the fight against this pandemic."

Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Officer, Johnson & Johnson, said, "We greatly value the U.S. government's confidence and support for our R&D efforts. Johnson & Johnson's global team of experts has ramped up our research and development processes to unprecedented levels, and our teams are working tirelessly alongside BARDA, scientific partners, and global health authorities. We are very pleased to have identified a lead vaccine candidate from the constructs we have been working on since January. We are moving on an accelerated timeline toward Phase 1 human clinical trials at the latest by September 2020 and, supported by the global production capability that we are scaling up in parallel to this testing, we expect a vaccine could be ready for emergency use in early 2021."

Johnson & Johnson's Lead COVID-19 Vaccine Candidate

Johnson & Johnson began efforts in January 2020, as soon as the novel coronavirus (COVID-19) sequence became available, to research potential vaccine candidates. Research teams at Janssen, in collaboration with Beth Israel Deaconess Medical Center, part of Harvard Medical School, constructed and tested multiple vaccine candidates using the Janssen AdVac® technology.

Through collaborations with scientists at multiple academic institutions, the vaccine constructs were then tested to identify those with the most promise in producing an immune response in preclinical testing.

Based on this work, Johnson & Johnson has identified a lead COVID-19 vaccine candidate (with two back-ups), which will progress into the first manufacturing steps. Under an accelerated timeline, the Company is aiming to initiate a Phase 1 clinical study in September 2020, with clinical data on safety and efficacy expected to be available by the end of the year. This could allow vaccine availability for emergency use in early 2021. For comparison, the typical vaccine development process involves a number of different research stages, spanning 5 to 7 years, before a candidate is even considered for approval.

For more than 20 years, Johnson & Johnson has invested billions of dollars in antivirals and vaccine capabilities. The COVID-19 vaccine program is leveraging Janssen's proven AdVac® and PER.C6® technologies that provide the ability to rapidly develop new vaccine candidates and upscale production of the optimal vaccine candidate. The same technology was used to develop and manufacture the Company's Ebola vaccine and construct our Zika, RSV, and HIV vaccine candidates which are in Phase 2 or Phase 3 clinical development stages.

Expanded Antiviral Research

In addition to the vaccine development efforts, BARDA and Johnson & Johnson have also expanded their partnership to accelerate Janssen's ongoing work in screening compound libraries, including compounds from other pharmaceutical companies. The Company's aim is to identify potential treatments against the novel coronavirus. Johnson & Johnson and BARDA are both providing funding as part of this partnership. These antiviral screening efforts are being conducted in partnership with the Rega Institute for Medical Research (KU Leuven/University of Leuven), in Belgium.

As announced in February 2020, the Company and BARDA have been working closely with global partners to screen Janssen's library of antiviral molecules to accelerate the discovery of potential COVID-19 treatments.

COVID-19 belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no approved vaccine, treatment or cure for COVID-19.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com





Other Headlines:

Cognizant to Acquire Contino, a Premier Enterprise DevOps and Cloud Transformation Consultancy

Anil Kapur Joins MoneyGram as Head of Asia Pacific and South Asia

Cognizant Resolves Previously Disclosed FCPA Matter with U.S. Authorities

Cognizant announces Q4 results

Cognizant Named to Barron's 100 Most Sustainable Companies List

Strengthening labour market and firming up of economic activity allows US Fed to raise rates: Angel Broking

Cognizant Acquires Brilliant Service, a Japan-Based Intelligent Products and Solutions Company

Cognizant Named a Leader in Gartner Magic Quadrant for Managed Workplace Services in North America

Clean Motion listed on Nasdaq First North stock exchange on 26th of May 2016

NETGEAR Rolls out two industry-first series of ProSAFE(R) 10Gigabit (10G) switches

Genpact Schedules Earnings Announcement and Conference Call for First Quarter 2016 Results

Cisco Cloud Index Projects that Cloud Traffic in Middle East and Africa will quadruple by 2019

Bonnier Group Selects Cognizant For Finance and Accounting Services

New Cognizant Digital Healthcare Platform Drives Business Outcomes through Increased Consumer Engagement

Cognizant Named a Top Employer Across Europe for 2016 Based on Its Talent, Learning and Development Strategies

FedEx Cares Campaign Celebrated Across 34 Cities in India

Kuwait Oil Company Opts for Cisco Security Solutions for High-Security Network

NETGEAR Launches business product selector tool for Network management on Android and iOS Devices

Barracuda Introduces New Cloud Archiving Service

Etihad Airways Partners with Cognizant to Reimagine Digital Guest Experience Across the Group

NETGEAR flaunts R7000 Nighthawk AC1900 Smart WiFi Router with Enhanced Features

NETGEAR Founder & CEO Mr Patrick Lo unveils India growth plan

Cognizant Named to "Winner's Circle" for Internet of Things Service Providers in New HfS Research Report

Cognizant Named to Healthcare Payer Operations "Winner's Circle" in HfS Research Report

Red Hat Named a Leader in Mobile Infrastructure Services by Independent Research Firm

Johnson & Johnson India's 'I Pledge to Breastfeed' Campaign

Medtronic launches Resolute Onyx™ Drug-Eluting Stent in India

Barracuda Ranked Number One in Integrated Systems for Purpose Built Backup Appliance Units Shipped

Cognizant reaffirms 2015 Guidance

Red Hat Enterprise Linux for SAP HANA® Available on Amazon Web Services

Delhi Gourmet Club and Groupon India launch 'The Gourmet Studio'

Cognizant Partners with supermarket retailer NTUC FairPrice, Singapore

Cisco Embeds Security Everywhere Across the Extended Network Enabling Organizations

NETGEAR introduces 100% wireless HD Smart Home Security System in India

Cisco To Address Security Of Everything at IoTX 2015

Lumenis Deploys Cognizant's MedVantage

Cognizant Named a Top IT Infrastructure Transformation Consulting Provider by Kennedy Consulting Research and Advisory

Cisco Launches New Advanced Malware Protection Capabilities And Incident Response Services For Customers At GISEC 2015

StoreHippo commences Marketplace Integration for eBay and Amazon

Unisys Forward!Model 4150B Server Achieves Certification to Run on SAP HANA®

Dramatic Impact of Intelligent Process Automation; Software Robots Making Business Smarter - Cognizant Study

Consortium of More than 25 Airlines Chooses Unisys System to Manage Baggage Reconciliation Process at Australian Airports

Tryg Insurance Selects Cognizant

Cognizant Named a "Leader" in B2C Global Commerce Service Provider Report by Independent Research Firm

Unisys Teams with ServiceNow to Deliver New Integrated Service Management Solutions

NETGEAR AnnouncesReadyNAS 3130 Series Network Attached Storage devices

NETGEAR Builds Stronger SMB Networking With ProSAFE WC9500 Premium Wireless Controller

Unisys Announces Winners of Cloud 20/20 Version 6.0 Technical Project Contest

Family Dollar Deploys Cognizant's Cloud360 Platform to Boost Business Responsiveness and Drive Growth

Cognizant Recognized as "Market Leader" in Ovum Decision Matrix on Outsourced Testing Service Providers







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019